Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Nifekalant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 3/20 | 0.98 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.98 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.98 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.98 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.98 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.98 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nifekalant SCHEMBL157527 | 0.99 | KCNH2 (1.00) | KCNH2SLC22A2ADRB1SLC6A4SLC47A2 | |
| Nifekalant SCHEMBL1649642 | 0.97 | KCNH2 (0.96) | KCNH2SLC22A2ADRB1SLC6A4SLC47A2 | |
| SCHEMBL9386021 | 0.96 | KCNH2 (0.94) | KCNH2SLC22A2ADRB1SLC6A4SLC47A2 | |
| SCHEMBL9389997 | 0.95 | KCNH2 (0.93) | KCNH2SLC22A2ADRB1SLC6A4SLC47A2 | |
| SCHEMBL9386126 | 0.94 | KCNH2 (0.91) | KCNH2SLC22A2ADRB1SLC6A4SLC47A2 | |
| SCHEMBL9388704 | 0.93 | KCNH2 (0.89) | KCNH2SLC22A2ADRB1SLC6A4SLC47A2 | |
| Nifekalant SCHEMBL10430098 | 0.93 | KCNH2 (0.88) | KCNH2SLC22A2ADRB1SLC6A4SLC47A2 | |
| SCHEMBL9384098 | 0.93 | KCNH2 (0.88) | KCNH2SLC22A2ADRB1SLC6A4SLC47A2 | |
| Oxalic Acid SCHEMBL9386654 | 0.92 | KCNH2 (0.86) | KCNH2SLC22A2ADRB1SLC6A4SLC47A2 | |
| SCHEMBL9388202 | 0.91 | KCNH2 (0.86) | KCNH2SLC22A2ADRB1SLC6A4SLC47A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113747562-B | SR prohibit timer duration setting method, system, intelligent device and storage medium | 上海擎昆信息科技有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-102449165-A | Genetic markers for risk management of atrial fibrillation and stroke | DECODE GENETICS EHF | 2012-05-09 | — | — | CN | claimed |
| EP-2414543-A1 | GENETIC MARKERS FOR RISK MANAGEMENT OF ATRIAL FIBRILLATION AND STROKE | Decode Genetics EHF (IS) | 2012-02-08 | — | — | EP | claimed |
| US-20120021989-A1 | GENETIC MARKERS FOR RISK MANAGEMENT OF ATRIAL FIBRILLATION AND STROKE | DECODE GENETICS EHF. (IS) | 2012-01-26 | — | — | US | claimed |
| WO-2011042920-A1 | GENETIC VARIANTS INDICATIVE OF VASCULAR CONDITIONS | DECODE GENETICS EHF (IS) | 2011-04-14 | — | — | WO | claimed |
| WO-2010113185-A1 | GENETIC MARKERS FOR RISK MANAGEMENT OF ATRIAL FIBRILLATION AND STROKE | DECODE GENETICS EHF (IS) | 2010-10-07 | — | — | WO | claimed |
| US-20090325163-A1 | GENETIC MARKERS FOR RISK MANAGEMENT OF CARDIAC ARRHYTHMIA | DECODE GENETICS EHF (IS) | 2009-12-31 | — | — | US | claimed |
| EP-2121979-A2 | GENETIC MARKERS FOR RISK MANAGEMENT OF CARDIAC ARRHYTHMIA | Decode Genetics EHF (IS) | 2009-11-25 | — | — | EP | claimed |
| WO-2008068780-A2 | GENETIC MARKERS FOR RISK MANAGEMENT OF CARDIAC ARRHYTHMIA | DECODE GENETICS EHF. (IS) | 2008-06-12 | — | — | WO | claimed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| US-12564594-B2 | Pharmaceutical composition containing 9-ethyl-6, 6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-03-03 | — | — | US | disclosed |
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4681715-A2 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4076450-B1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS INC (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-1797900-A1 | PREPARATION FOR PERCUTANEOUS/PERMUCOSAL ABSORPTION | KABUSHIKI KAISHA SANGI (JP) | 2007-06-20 | — | — | EP | disclosed |
| US-20070135412-A1 | Compounds for the treatment of ocular dryness caused by photorefractive surgery | UNIVERSIDAD MIGUEL HERNANDEZ (ES) | 2007-06-14 | — | — | US | disclosed |
| EP-1743895-A1 | MUSCLE RELAXATION ACCELERATOR AND THERAPEUTIC AGENT FOR MUSCULAR TISSUE DISEASES SUCH AS MUSCLE RELAXATION FAILURE | AETAS PHARMA CO., LTD. (JP) | 2007-01-17 | — | — | EP | disclosed |
| EP-1700616-A1 | COMPOUNDS FOR THE TREATMENT OF OCULAR DRYNESS CAUSED BY PHOTOREFRACTIVE SURGERY | Universidad Miguel Hernandez de Elche (ES) | 2006-09-13 | — | — | EP | disclosed |
| EP-0722732-A1 | Long-acting drug formulation containing pyrimidinedione derivatives | MITSUI TOATSU CHEMICALS, INC. (JP) | 1996-07-24 | — | — | EP | disclosed |
| EP-0640341-A1 | Sustained release pharmaceutical composition and process for producing same | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | KCNH2 2560/4885ADRB1 797/4885SLC6A4 3351/4885 |
| US-12564594-B2 | Pharmaceutical composition containing 9-ethyl-6, 6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile | KCNN2, KCNN1, KIT | KCNH2 739/4885ADRB1 2562/4885SLC6A4 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.